Interestingly, while these studies shown that the inhibition of such targets are linked to the impaired viability of BRCA1-deficient cells in vitro, these types of approaches are not yet established as alternatives for the treatment of BRCA1-related cancers. This evidence concerns the gene BRCA1 and cancer.